Weight Loss Pills Are Coming Soon!
Weight-loss drugs are expected to pull in more than $150 billion in industry-wide revenue by the early 2030s, thanks to the ever-growing popularity of Eli Lilly’s (LLY.N), Zepbound and Novo Nordisk’s (NOVOb.CO), Wegovy. Both the GLP-1 weight loss drugs are weekly injections, although several drugmakers are racing to develop an oral medicine or pill that might prove to be as effective as the injectables.
Pills are easier to manufacture and could also avoid some of the supply issues that were initially seen with Novo and Lilly’s drugs. Here are some companies developing oral obesity drugs in the hopes of making their mark in a lucrative market:
Eli Lilly: Orforglipron, the company’s once-daily oral non-peptide GLP-1 agonist, helped patients shed 12.4% of body weight over 72 weeks at the highest dose in a late-stage trial. Lilly plans to file for regulatory approval by the end of 2025 and is preparing for global submissions and manufacturing scale-up.
Excerpted from Reuters
